Skip to content

Frank Wiegand

4 papers in the library · 519 citations · publishing 2015-2024

Papers

Sort Most recent Most cited

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants.

Journal of psychopharmacology (Oxford, England) August 1, 2024 James Jonathan Rucker, Claire T. Roberts, Mathieu Seynaeve et al. 32 citations

To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003, a novel intranasal benzoate salt formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), in healthy participants. In all, 44 psychedelic-naïve participants enrolled in the double-blind, placebo-controlled single ascending dose study (1-12 mg BPL-003). Concentrations of 5-MeO-DMT and its...

Psychedelics for Medicinal Use: How Will This Alter the Collective Laboratory Consciousness?

Clinical Chemistry March 7, 2023 Steven W. Cotten, Frederick G. Strathmann, Frederick S. Barrett et al.

The clinical evaluation of hallucinogens and other small molecules, conventionally termed psychedelics, has seen a dramatic increase in the past 5 years. Several key clinical trials recently demonstrated the potential efficacy of these compounds in treating a variety of mental health conditions including depression, anxiety, and substance use disorders. Concurrently, the business and patent...

Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data

The International Journal of Neuropsychopharmacology April 7, 2020 Michel Nijs, Ewa Wajs, Leah Aluisio et al. 21 citations

BACKGROUND: Esketamine nasal spray was recently approved for treatment-resistant depression. The current analysis evaluated the impact of symptom-based treatment frequency changes during esketamine treatment on clinical outcomes. METHODS: This is a post-hoc analysis of an open-label, long-term (up to 1 year) study of esketamine in patients with treatment-resistant depression (SUSTAIN 2). During...

Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study

Biological Psychiatry November 4, 2015 Jaskaran Singh, Maggie Fedgchin, Ella Daly et al. 466 citations

BACKGROUND: The purpose of this study was to assess the efficacy and safety and to explore the dose response of esketamine intravenous (IV) infusion in patients with treatment-resistant depression (TRD). METHODS: This multicenter, randomized, placebo-controlled trial was conducted in 30 patients with TRD. Patients were randomly assigned 1:1:1 to receive an IV infusion of .20 mg/kg or .40 mg/kg...